Erin Cockrell
Pediatric Hematology-Oncology · Tampa, FLNPI 1255531455
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 62.1% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $62,226, 2.4 times the $26,075 reported in 2019. Among pediatric hematology-oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $980.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$161K
- Genentech USA, Inc.$52K
- Novo Nordisk$19K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- CSL Behring$6K
- Bayer$4K
- plus $10K from 21 others
Across 223 payments — averaging $3039.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$319K
- Sanofi US Services Inc.$171K
- Bioverativ Therapeutics Inc.$70K
- Novo Nordisk AS$68K
- Boehringer Ingelheim$25K
- Pfizer$21K
- plus $4K from 4 others
What the payments were for
- Consulting fees$142,24855%
- Speaking & faculty fees$89,26334%
- Travel & lodging$20,2968%
- Food & beverage$7,5603%
- Education$5030%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 113 | $161,478 |
| Genentech USA, Inc. | 54 | $51,584 |
| Novo Nordisk | 12 | $19,008 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $8,495 |
| CSL Behring | 11 | $5,534 |
| Bayer | 7 | $3,545 |
| Bioverativ Therapeutics Inc. | 2 | $2,862 |
| Global Blood Therapeutics, Inc. | 4 | $2,691 |
| HEMA Biologics, LLC | 6 | $2,515 |
| Biomarin Pharmaceutical Inc. | 3 | $387 |
| Jazz Pharmaceuticals Inc. | 6 | $357 |
| Novartis | 10 | $281 |
| Octapharma USA, Inc. | 3 | $211 |
| Astellas Pharma US Inc | 4 | $199 |
| Servier Pharmaceuticals LLC | 1 | $140 |
| Springworks Therapeutics, Inc. | 4 | $103 |
| Amgen | 2 | $98 |
| AstraZeneca(2 entities) | 5 | $96 |
| Pfizer | 2 | $65 |
| Genentech, Inc. | 2 | $54 |
| Agios Pharmaceuticals, Inc. | 2 | $42 |
| USWM, LLC | 2 | $39 |
| Y-mabs Therapeutics, Inc. | 1 | $25 |
| RARE Disease Therapeutics, Inc. | 1 | $22 |
| Janssen Scientific Affairs, LLC | 1 | $19 |
| Terumo BCT, Inc. | 1 | $17 |
| Emmaus Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$259,881 in reported general payments places this provider in the 95th percentile of 132 pediatric hematology-oncology providers in Florida.
See all pediatric hematology-oncology providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 13 | $384 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Tampa
- Dana ObzutTampa$93K
- Damon ReedTampa$9K
- Don EslinTampa$5K
- Trisha LarkinTampa$4K
- Simone ChangTampa$2K
- Juan RicoTampa$1K
- Deepakbabu ChellapandianTampa$1K
- Diana LoneTampa$1K
- Guillermo DeanguloMiami$929K
- Shveta GuptaOrlando$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.